Cytek Biosciences Stock Performance
| CTKB Stock | USD 6.53 0.03 0.46% |
On a scale of 0 to 100, Cytek Biosciences holds a performance score of 6. The firm shows a Beta (market volatility) of 4.73, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Cytek Biosciences will likely underperform. Please check Cytek Biosciences' expected short fall, day median price, and the relationship between the potential upside and accumulation distribution , to make a quick decision on whether Cytek Biosciences' price patterns will revert.
Risk-Adjusted Performance
6 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Cytek Biosciences are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Despite somewhat uncertain forward-looking signals, Cytek Biosciences sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 1.4 | Five Day Return (0.15) | Year To Date Return (26.72) | Ten Year Return (65.35) | All Time Return (65.35) |
1 | Disposition of 200000 shares by Wenbin Jiang of Cytek Biosciences subject to Rule 16b-3 | 09/13/2024 |
2 | Cytek Biosciences, Inc.s Intrinsic Value Is Potentially 99 percent Above Its Share Price | 09/18/2024 |
3 | Deerfield Management Company L.P. Series C Acquires Shares of 155,759 Cytek Biosciences, Inc. - MarketBeat | 09/27/2024 |
4 | Acquisition by Allen Poirson of 2503 shares of Cytek Biosciences subject to Rule 16b-3 | 10/11/2024 |
5 | Acquisition by Imper Vera of 15706 shares of Cytek Biosciences subject to Rule 16b-3 | 10/15/2024 |
6 | Acquisition by Paul Williams of 8840 shares of Cytek Biosciences subject to Rule 16b-3 | 10/18/2024 |
7 | Codexis Reports Q3 Loss, Tops Revenue Estimates | 10/31/2024 |
8 | Cytek Biosciences, Inc. Q3 Earnings and Revenues Beat Estimates | 11/05/2024 |
9 | Cytek Biosciences Announces Quarterly Earnings Results | 11/06/2024 |
10 | Cytek Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell Sorter | 11/07/2024 |
11 | Acquisition by Holder Michael of 2181 shares of Cytek Biosciences subject to Rule 16b-3 | 11/18/2024 |
12 | Disposition of 1235 shares by Barnett Valerie of Cytek Biosciences at 6.03 subject to Rule 16b-3 | 11/20/2024 |
13 | Acquisition by Barnett Valerie of 2016 shares of Cytek Biosciences subject to Rule 16b-3 | 11/27/2024 |
| Begin Period Cash Flow | 299.5 M |
Cytek |
Cytek Biosciences Relative Risk vs. Return Landscape
If you would invest 539.00 in Cytek Biosciences on August 31, 2024 and sell it today you would earn a total of 114.00 from holding Cytek Biosciences or generate 21.15% return on investment over 90 days. Cytek Biosciences is currently generating 0.4418% in daily expected returns and assumes 5.6782% risk (volatility on return distribution) over the 90 days horizon. In different words, 50% of stocks are less volatile than Cytek, and 92% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cytek Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cytek Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cytek Biosciences, and traders can use it to determine the average amount a Cytek Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0778
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CTKB | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.68 actual daily | 50 50% of assets are less volatile |
Expected Return
| 0.44 actual daily | 8 92% of assets have higher returns |
Risk-Adjusted Return
| 0.08 actual daily | 6 94% of assets perform better |
Based on monthly moving average Cytek Biosciences is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cytek Biosciences by adding it to a well-diversified portfolio.
Cytek Biosciences Fundamentals Growth
Cytek Stock prices reflect investors' perceptions of the future prospects and financial health of Cytek Biosciences, and Cytek Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cytek Stock performance.
| Return On Equity | -0.0254 | ||||
| Return On Asset | -0.0274 | ||||
| Profit Margin | (0.05) % | ||||
| Operating Margin | (0.08) % | ||||
| Current Valuation | 574.01 M | ||||
| Shares Outstanding | 128.81 M | ||||
| Price To Book | 2.17 X | ||||
| Price To Sales | 4.16 X | ||||
| Revenue | 193.01 M | ||||
| Gross Profit | 100.97 M | ||||
| EBITDA | (4.41 M) | ||||
| Net Income | (12.15 M) | ||||
| Cash And Equivalents | 349.89 M | ||||
| Cash Per Share | 2.60 X | ||||
| Total Debt | 14.14 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 10.47 X | ||||
| Book Value Per Share | 2.97 X | ||||
| Cash Flow From Operations | 5.28 M | ||||
| Earnings Per Share | (0.08) X | ||||
| Market Capitalization | 837.27 M | ||||
| Total Asset | 494.46 M | ||||
| Retained Earnings | (29.18 M) | ||||
| Working Capital | 335.83 M | ||||
About Cytek Biosciences Performance
By analyzing Cytek Biosciences' fundamental ratios, stakeholders can gain valuable insights into Cytek Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Cytek Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cytek Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 265.83 | 195.16 | |
| Return On Tangible Assets | (0.03) | (0.03) | |
| Return On Capital Employed | (0.06) | (0.06) | |
| Return On Assets | (0.02) | (0.03) | |
| Return On Equity | (0.03) | (0.03) |
Things to note about Cytek Biosciences performance evaluation
Checking the ongoing alerts about Cytek Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cytek Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cytek Biosciences had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 193.01 M. Net Loss for the year was (12.15 M) with profit before overhead, payroll, taxes, and interest of 100.97 M. | |
| Cytek Biosciences has a poor financial position based on the latest SEC disclosures | |
| About 59.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Acquisition by Barnett Valerie of 2016 shares of Cytek Biosciences subject to Rule 16b-3 |
- Analyzing Cytek Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cytek Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Cytek Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cytek Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cytek Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cytek Biosciences' stock. These opinions can provide insight into Cytek Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Cytek Stock analysis
When running Cytek Biosciences' price analysis, check to measure Cytek Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytek Biosciences is operating at the current time. Most of Cytek Biosciences' value examination focuses on studying past and present price action to predict the probability of Cytek Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cytek Biosciences' price. Additionally, you may evaluate how the addition of Cytek Biosciences to your portfolios can decrease your overall portfolio volatility.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Stocks Directory Find actively traded stocks across global markets | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |